Bivalirudin for Primary Percutaneous Coronary Interventions | Zendy

Benjamin Hibbert | Zendy; Andrea MacDougall | Zendy; Marino Labinaz | Zendy; Edward R. O’Brien | Zendy; Derek So | Zendy; Alexander Dick | Zendy; Christopher Glover | Zendy; Michael Froeschl | Zendy; Jean-François Marquis | Zendy; George A. Wells | Zendy; M Blondeau | Zendy; Michel R. Le May | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bivalirudin for Primary Percutaneous Coronary Interventions

Author(s) -

Benjamin Hibbert,

Andrea MacDougall,

Marino Labinaz,

Edward R. O’Brien,

Derek So,

Alexander Dick,

Christopher Glover,

Michael Froeschl,

Jean-François Marquis,

George A. Wells,

M Blondeau,

Michel R. Le May

Publication year - 2012

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.112.968966

Subject(s) - bivalirudin , percutaneous , medicine , psychological intervention , cardiology , percutaneous coronary intervention , myocardial infarction , nursing

Data from randomized trials has demonstrated the superiority of bivalirudin to glycoprotein IIb/IIIa inhibitors plus heparin in patients undergoing primary percutaneous coronary intervention. Real-world performance of bivalirudin in primary percutaneous coronary intervention and the benefit of bivalirudin over heparin remain unknown in an era of routine dual antiplatelet therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research